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Pax genes: regulators of lineage specification and progenitor cell
maintenance
Judith A. Blake* and Melanie R. Ziman
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Introduction

Paired box (Pax) genes encode transcription factors that contain a
highly conserved DNA-binding domain called the paired domain (PD,
Fig. 1A) and can be considered to be a principle regulator of gene
expression. Nine Pax genes (Pax1-Pax9) have been characterised in
mammals and the evolutionary conserved paired domain has been
identified across phylogenies from insects, to amphibians and birds.
In higher vertebrates, PAX proteins are subclassified into groups
according to inclusion of an additional DNA-binding homeodomain
and/or an octapeptide region, which serves as a binding motif for
protein co-factors for potent inhibition of downstream gene
transcription (Eberhard et al., 2000) (Fig. 1B); all PAX proteins
include a transactivation domain located within the C-terminal amino
acids (Underhill, 2012). It is also known that all Pax genes, with the
exception of Pax4 and Pax9, produce alternative RNA transcripts (see
Table 1). The functional diversity of Pax proteins in vivo is thus linked
to the ability to produce alternatively spliced gene products that differ
in structure and, consequently, in the binding activity of their paired
and homeodomain DNA-binding regions (Underhill, 2012).
Three decades ago, the characterisation and roles of Pax genes in
embryonic development began to unfold. Early studies discovered that
regulatory gene families such as the Pax family are involved in the
sequential compartmentalisation and body patterning of developing
organisms; thereafter, studies highlighted a role for Pax genes in the
early specification of cell fate and the subsequent morphogenesis of
various tissues and organs. Following this, mutational studies of Pax
genes confirmed the importance of these regulatory roles in the
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initiation and progression of development, as well as in disease. The
aim of this Primer is to highlight the means by which PAX
transcription factors function and to discuss the molecular
mechanisms used to determine their tissue-specific activity.
Developmental roles for Pax genes

Studies in animals, together with analyses of human genetics, have
revealed important roles for Pax genes (summarised in Table 2) in
the development of various organs and tissues, including the thymus
(PAX1 and PAX7), vertebrae (PAX1), ear (PAX2 and PAX8), kidney
(PAX2), central nervous system (CNS) (PAX2, PAX5, PAX8, PAX6,
PAX3 and PAX7), heart vasculature, enteric nervous system,
melanocytes, Schwann cells (PAX3 and PAX7), pancreas (PAX4 and
PAX6), B lymphocytes (PAX5), eye (PAX6), skeletal muscle (PAX3
and PAX7), thyroid (PAX8) and teeth (PAX 7 and PAX9)
(Lechtenberg and Ferretti, 1981; Tassabehji et al., 1992; Hoth et al.,
1993; Barr et al., 1996; Wallin et al., 1996; Epstein, 1996; St-Onge
et al., 1997; Macchia et al., 1998; Nutt and Busslinger, 1999; Eccles
and Schimmenti, 1999; Lang et al., 2000; Stockton et al., 2000;
Adham et al., 2005). In order to understand how PAX transcription
factors regulate patterns of gene expression and control cellular
development, it is essential to determine the mechanisms by which
PAX proteins operate, although this has been a major challenge.
Pax6 is one of the most extensively studied members of the Pax
family. It not only regulates development of the CNS and is
implicated in CNS disease, but also has an important role in the
survival of healthy adult brain neurons and their vulnerability to
neurodegeneration. Thus, the functional mechanisms of Pax6 action
during CNS development have been widely studied and are
highlighted here. Pax gene function has also been well characterised
during embryonic development of the musculoskeletal system,
which is described as a progressive process in which cells undergo
lineage determination through the restriction of their cellular
potential. In this system, research has aided our understanding of the
molecular mechanisms by which Pax genes function to specify cell
identity and to regulate this progressive process, which also has
important implications for adult regenerative tissue repair and stem
cell research. Therefore, somitic development is also the focal point
of this Primer. In contrast to somitic cell progenitors, neural crest
progenitors acquire a greater developmental potential than the cells
from which they are derived and display stem cell characteristics,
such as the maintenance of multipotency and the repression of
differentiation via genetic and epigenetic mechanisms. The
mechanisms by which Pax3 governs differentiation in neural crest
precursors is of great interest to developmental biologists and for
regenerative medicine; thus, the molecular influence of Pax3 in the
cells derived from the neural crest is also discussed here.
PAX6 coordinates specification of the neuroectoderm

PAX6 plays an important role as early as the second week following
human conception, when the formation of the CNS commences, as
737
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ABSTRACT
Pax genes encode a family of transcription factors that orchestrate
complex processes of lineage determination in the developing
embryo. Their key role is to specify and maintain progenitor cells
through use of complex molecular mechanisms such as alternate
RNA splice forms and gene activation or inhibition in conjunction with
protein co-factors. The significance of Pax genes in development is
highlighted by abnormalities that arise from the expression of mutant
Pax genes. Here, we review the molecular functions of Pax genes
during development and detail the regulatory mechanisms by which
they specify and maintain progenitor cells across various tissue
lineages. We also discuss mechanistic insights into the roles of Pax
genes in regeneration and in adult diseases, including cancer.
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radial glia (Suter et al., 2009), suggesting distinct roles for PAX6 in
human versus mouse NE specification.
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Fig. 1. Subclassification of PAX transcription factors according to
protein structure. (A) All PAX proteins contain a transactivation domain and
a DNA-binding domain known as the paired domain (PD). The PD consists of
PAI and RED subdomains, each of which is composed of three helices in a
helix-turn-helix motif. Some PAX family members also contain an additional
DNA-binding homeodomain and/or an octapeptide region. (B) PAX proteins
are subclassified into four paralogous groups according to full or partial
inclusion of the additional DNA-binding homeodomain and the octapeptide
region. Adapted, with permission, from Chi and Epstein (Chi and Epstein,
2002).

the neuroectoderm (NE) is specified from the pluripotent epiblast.
In humans, there is evidence that PAX6 is necessary for NE
specification from embryonic stem cells where it functions to
repress the pluripotency genes Oct4, Nanog and Myc and in turn
initiate differentiation toward a NE fate. However, PAX6-mediated
repression of pluripotency genes is not sufficient for induction of NE
differentiation; the PAX6A isoform (Table 1) binds to and induces
downstream NE layer genes such as Lhx2 (LIM homeobox protein
2), Six3 (sine oculis-related homeobox 3), Fgf8 (fibroblast growth
factor 8) and Wnt5b, while a second isoform, PAX6B, potentiates
the NE inductive effects of PAX6A through co-repression of
pluripotent genes (Zhang et al., 2010). Importantly, these findings
are in contrast to those observed during mouse NE specification,
where Pax6 is expressed following the formation of NE cells
(Bylund et al., 2003) and is linked to the progression of NE cells to
738

PAX-controlled regionalisation of the neural tube

Pax2 is the earliest Pax gene to be expressed during mouse
neurulation, exhibiting expression at embryonic day 7.5 (E7.5) in
the neural plate area of the future mid/hindbrain region, where it
is essential for formation of the midbrain-hindbrain boundary
(MHB), which controls midbrain and cerebellar development
(Pfeffer et al., 2002). Subsequently, Pax5 and Pax8 are also
expressed in this region, where their temporal sequence of
activation is crossregulated by PAX2. In Pax2 mutant embryos,
Pax5 expression is absent from the MHB and this loss is linked to
loss of PAX-mediated regulation of the MHB-specific enhancer of
Pax5 (Pfeffer et al., 2000). Interestingly, Pax2 expression in the
MHB is controlled by early and late enhancers, the latter of which
is auto- and crossregulated by PAX5 and PAX8, respectively
(Pfeffer et al., 2002). These crossregulatory feedback loops are
thought to ‘maintain, sharpen and stabilise’ the Pax2 domain at the
MHB (Pfeffer et al., 2002).
Around the fourth week of human gestation, the cephalic end of
the neural tube forms three brain vesicles, which correspond to
the forebrain (telencephalon and diencephalon), midbrain
(mesencephalon)
and
hindbrain
(metencephalon
and
myeloencephalon). The formation of these various rudimentary
brain structures is brought about by boundary formation and neural
progenitor specification. Regionalisation of the neural tube by
boundary formation is evident as early as E8 in mouse, when Pax6
and Pax2 transcripts are first detected in the presumptive forebrain
and midbrain where their expression corresponds to the
establishment of a boundary between the di- and mesencephalic
areas (Walther and Gruss, 1991). It has been proposed by Matsunaga
et al. (Matsunaga et al., 2000) that Pax6 is induced in the rostral
region as Pax2 is induced in the caudal region, giving rise to an
overlap of Pax6 and Pax2 expression at the di-mesencephalic
boundary. In this region, Pax6 and Pax2 are proposed to repress
each other, by indirect and direct molecular mechanisms, until their
expression domains are completely segregated, thus forming the dimesencephalic boundary (Fig. 2). Altered regionalisation, such as
that occurring in Pax6 mutant mice, leads to a misexpression of
genes that is characteristic of the neighbouring brain region and
ultimately a change in the neuronal fate of that region (Mastick et
al., 1997; Schwarz et al., 1999). Thus, the direct and indirect effects
of Pax gene expression and regionalisation leading to patterning of
the brain are tightly controlled.
An example of the series of positive and negative regulatory
events involved in early brain regionalisation is seen during
specification of the optic tectum, which is linked to the activities of
Pax3 and Pax7, and of the transcription factors Meis2 (Meis
homeobox 2) and Otx2 (orthodenticle homolog 2). Otx2 expression
is a prerequisite for development of all anterior brain structures and
is present in the entire neural tube anterior to the MHB (Acampora
et al., 1995). Meis2 competes with Groucho co-repressor Tle4 for
binding to Otx2, and formation of Meis2/Otx2 complexes confers
tectal specificity in the dorsal midbrain. Meis2, however,
autostimulates its expression in the tectal anlage; therefore, an
inhibitory mechanism is required to prevent overexpression and
faithfully demarcate the prospective tectal area (Agoston and
Schulte, 2009). Using chick in ovo electroporation gain-of-function
Pax3/7 experiments, it has been reported that tectal expression of
Meis2 is balanced by Pax3/7 regulation. Moreover, Meis2 not only
associates with Otx2 but interacts with Pax3 and Pax7 in order to

Development

Paired DNA-binding domain

A

function both as a transcriptional activator of downstream tectumassociated genes and to repress the diencephalic marker Pax6
(Agoston et al., 2012).
PAX6 functions in the developing spinal cord

As regionalisation and specification of the neurons of the developing
brain occurs, the remainder of the caudal neural tube forms the
spinal cord, in which the distinction of neuronal cell subtypes that
will control either sensory input or motor output is controlled by
intricate gene regulatory networks. Motoneurons differentiate from
progenitor cells via graded sonic hedgehog (Shh) protein signals
secreted from the notochord and floorplate. Concentrations of Shh
ligands are said to be ‘interpreted’ by progenitor cells so as to
initially define their identity and position into four distinct neuronal
subtypes within the ventral spinal cord (Ericson et al., 1997).
Although a relationship between Shh, Olig2 (oligodendrocyte
transcription factor 2), Pax6 and Nkx2.2 (NK2 homeobox 2) has
been demonstrated, whereby Pax6 and Nkx2.2 were affected
inversely by rising concentrations of Shh (Ericson et al., 1997), this
model was challenged in terms of the direct effects of morphogen
gradients and was further tuned to incorporate non-graded feedback
circuits between Shh, Olig2, Pax6 and Nkx2.2; Nkx2.2 intrinsically
strengthens Shh responses by positive feedback, whereas Pax6 is a
Shh antagonist (Lek et al., 2010).
Further studies of neuroblast specification demonstrated that the
response of neuroblasts to Shh was linked to factors other than
transcriptional sensitivity to Shh signals. Using an in vivo reporter,
intracellular activity of Gli (a transcriptional effector of Shh
signalling) was found to be part of a Pax6-Olig2-Nkx2.2
transcriptional regulatory network (Balaskas et al., 2012). A
mathematical model of the network was tested using simulated
temporal and spatial changes in Gli activity, and graded gene
expression outputs of neuroblasts were shown to be a product of the
regulatory ‘logic’ of the Pax6-Olig2-Nkx2.2 network (Balaskas et
al., 2012). Thus, the level and duration of Shh signals did not alone
control neuroblast specification, as the regulatory network confers
robustness and insensitivity to transient changes in the level of Shh
signals (Balaskas et al., 2012).
In addition to specifying subsets of neurons in the developing
spinal cord, Pax6 also functions to control the balance between
neural progenitor proliferation and differentiation. Using gain and
loss of Pax6 expression experiments in the chick neural tube, it was
found that a threshold of Pax6 was crucial for cell cycle exit and
neuronal commitment. However, once the neural progenitor is
committed, Pax6 must be downregulated by neurogenin 2
(Neurog2) to allow differentiation (Bel-Vialar et al., 2007). This
characteristic Pax ‘on/off switch’ is said to temporally maintain a
precursor in a ‘pre-differentiation’ state and is recapitulated in
melanoblast and peripheral glioblast development (Kioussi et al.,
1995; Lang et al., 2005).
PAX6-mediated control of neurogenic proliferation and differentiation
in the cerebral cortex

In the developing mouse telencephalon, when the neural plate and
neural tube consist of a single cell layer of neuroepithelium, Pax6
controls the balance between neural stem cell self-renewal
(symmetric cell division) and neurogenesis (asymmetric cell
divisions that produce a neuron and a neurogenic progenitor)
(Sansom et al. 2009; Asami et al., 2011). Before neurogenesis,
neuroepithelial stem cells divide in a symmetric manner to yield
progenitors for the tangential growth of the cerebral cortex. Using
transcriptome-based analysis to follow changes in Pax6 levels in
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vivo, it was shown that Pax6 initially regulates neocortical cell cycle
progression by direct regulation of Hmga2 (high mobility group AThook 2), Tle1 (transducin-like enhancer of split 1) and Cdk4 (cyclindependent kinase 4), while it indirectly controls the expression of
cyclins, Hes5 (hairy and enhancer of split 5) and Notch ligands to
promote self-renewal. This temporal regulation of self-renewal is
then overcome by Pax6-mediated promotion of neurogenesis via
Neurog2 and Sox4 (sex-determining region Y, box 4), whereby an
increased dose of Pax6 pushes the system towards neurogenesis at
the expense of self-renewal (Sansom et al., 2009).
By E10/11, the neuroepithelium transforms into a number of cell
layers as neural stem cells lose epithelial features and give rise to
fate-restricted radial glia (RG) and basal progenitors (BPs). RG
remain confined to the lining of the ventricle (apical layer) where
their densely packed cell nuclei undergo mitosis in the ventricular
zone. BPs originate from neuroepithelial or RG at the apical surface
of the ventricular zone, but retract their apical cell processes at
mitosis and remain at the basal side of the ventricular zone to form
the subventricular zone. During neurogenic cell divisions, the
orientation of cleavage planes dictates whether the division will be
symmetric or asymmetric. Crucial apical and basal constituents
(such as those of the adherens junction) are thus either distributed
equally to daughter cells or apical constituents are inherited by one
daughter cell and basal constituents to the other. An increase in
asymmetric divisions of neurogenic progenitors of the neocortex has
been demonstrated in Pax6Sey/Sey mutant mice (Götz et al., 1998);
therefore, the cleavage angles of apical progenitors were assessed in
both Pax6Sey/Sey mice and a conditional Pax6 knockout model. In
both cases, Pax6 disruption significantly altered spindle orientation
in apical progenitors at mid-neurogenesis (E14-E16) into oblique
and horizontal planes. Alteration of the cleavage plane resulted in
the unequal inheritance of apical constituents, which prevented the
daughter cell from delaminating in the basal direction and resulted
in proliferative daughter cells with radial glial characteristics but
division at a sub-apical position. It was concluded that Pax6
regulates several components of apical junction coupling, in
particular Spag5 (sperm associated antigen 5), which is involved in
the localisation of spindle poles and kinetochores during cell
division (Asami et al., 2011).
The molecular mechanism by which Pax6 achieves either
proliferation or neurogenesis in neocortical cells is via distinct
functions of its paired domain subdomains. For example, using mice
with point mutations in either the PAI or the RED subdomain
(Fig. 1) and chromatin immunoprecipitation experiments, it was
demonstrated that distinct downstream target genes were
preferentially bound by either subdomain in vivo and that the PAI
subdomain has a role in decreasing cell mitoses while the RED
domain has the opposite effect. It was concluded that the coactivation of both proliferative and anti-proliferative genes acts to
fine-tune cell-cycle progression (Walcher et al., 2013). This
supposition is supported by the finding that Pax6 directs cortical cell
cycle progression in a regionally specific manner (Mi et al., 2013)
and that it does so through simultaneous expression of downstream
target gene sets through epigenetic regulation of chromatin
condensation in interaction with dynamically competitive BAF
subunits during the progression of neurogenesis (Tuoc et al., 2013).
Neural crest specification, migration and differentiation: the roles of
PAX3 and PAX7

Before the neural tube closes, a ridge of cells known as the neural
crest (NC) appears along the margins of the neural folds.
Melanocytes, neurons, peripheral glia, mesenchyme, facial
739
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Table 1. Alternative PAX transcripts
Function

Pax1 variant 1

Encodes the longest isoform of Pax1

Pax1 variant 2

Uses an alternate splice site in the 3 coding region, which results
in a frameshift compared with variant 1. Encodes an isoform that
has a shorter and distinct C terminus compared with variant 1.
Uses an alternate in-frame splice site in the 3 coding region
Cell differentiation during sensory placode
compared with variant e (see below) resulting in a shorter
formation (McCarroll et al., 2012); otic
protein that has a shorter, distinct C terminus compared with
specification (Hans et al., 2004)
variant e (see below)
Lacks an alternate in-frame exon and uses an alternate splice site Maintenance of the otic placode (Mackereth
in the 3 coding region compared with variant e (see below),
et al., 2005)
resulting in a protein with a shorter, distinct C-terminus
compared with variant e (see below)
Has multiple differences in the coding region compared with
variant e (see below), one of which results in a translational
frameshift. The resulting protein has a distinct C terminus and is
shorter than variant e.
Lacks an alternate in-frame exon compared with variant e (see
below). This results in an isoform that is shorter than variant e.
This variant encodes the longest isoform

Pax2 variant a

Pax2 variant b

Pax2 variant c

Pax2 variant d
Pax2 variant e
Pax3a

Pax3b

Pax3c

Pax3d

Pax3e

Pax3g

Pax3h

Pax4
Pax5
Pax6 variant 1

Pax6 variant 2

Pax6 variant 3

Pax6 variant 4

740

Differs in the 3 UTR, includes an alternate segment in the coding
Negative effects on melanocyte proliferation
region that causes a frameshift and lacks several segments in
(Wang et al., 2006)
the 3 coding region compared with isoform Pax3c. The resulting
protein lacks the paired-type homeodomain and has a shorter
and distinct C terminus compared with isoform Pax3c.
Differs in the 3 UTR, includes an alternate segment in the coding
Negative effects on melanocyte proliferation;
region that causes a frameshift and lacks several segments in
reduced migration and accelerated
the 3 coding region compared with isoform Pax3c. The resulting
apoptosis (Wang et al., 2006)
protein lacks the paired-type homeodomain and has a shorter
and distinct C terminus compared with isoform Pax3c.
The constitutive splice pattern. The resulting protein, PAX3C, is
Promotes melanocyte proliferation, migration,
also known as PAX3.
transformation and survival (Wang et al.,
2006);
required for terminal myogenic differentiation
(Charytonowicz et al., 2011)
Differs in the 3 UTR and contains an alternate splice pattern in the Promotes melanocyte proliferation, migration,
3 coding region compared with isoform Pax3c. The resulting
transformation and survival (Wang et al.,
protein is longer and has a distinct C terminus compared with
2006);
isoform Pax3c.
involved in undifferentiated cell maintenance
and/or proliferation (Charytonowicz et al.,
2011)
Differs in the 3 UTR and contains an alternate splice pattern in the Reduced melanocyte growth (Wang et al.,
3 coding region compared with isoform Pax3c. The resulting
2006)
protein is longer and has a distinct C terminus compared with
isoform Pax3c.
Differs in the 3 UTR and contains an alternate splice pattern in the Melanocyte migration was reduced (Wang et
3 coding region compared with isoform Pax3c. The resulting
al., 2007)
protein is shorter and has a distinct C terminus compared with
variant Pax3c.
Differs in the 3 UTR and contains an alternate splice pattern in the Increased melanocyte proliferation, migration,
3 coding region compared with isoform Pax3c. The resulting
survival and transformation (Wang et al.,
protein is shorter and has a distinct C terminus compared with
2006)
isoform Pax3c.
No data available on NCBI
No data available on NCBI
Also known as Pax6(5a). Represents the longest transcript.
Neurogenesis, proliferation, regionalisation
Variants 1, 3, 6 and 7 encode the same isoform (a).
and boundary formation
Also known as Pax6(+5a). Differs in the 5 UTR and includes an
insertion of 14 amino acids (exon 5a) into the paired domain
compared with variant 1. Variants 2, 4 and 5 encode the same
isoform (b), which is shorter than isoform a.
Differs in the 5 UTR compared to variant 1. Variants 1, 3, 6 and 7
encode the same isoform (a).

Overexpression leads to proliferation

Neurogenesis, proliferation, regionalisation
and boundary formation

Overexpression leads to proliferation
Differs in the 5 UTR and includes an alternate exon in the coding
region that maintains the reading frame compared with variant 1.
Variants 2, 4 and 5 encode the same isoform (b), which is
shorter than isoform a.

References
Burri et al., 1989;
Schnittger et al.,
1992
Burri et al., 1989;
Smith and Tuan,
1994
Eccles et al., 1992;
Ward et al., 1994

Eccles et al., 1992;
Ward et al., 1994

Eccles et al., 1992;
Ward et al., 1994

Tavassoli et al., 1997
Eccles et al., 1992;
Ward et al., 1994
Tassabehji et al.,
1992; CarezaniGavin et al., 1992

Tassabehji et al.,
1992; CarezaniGavin et al., 1992

Tassabehji et al.,
1992; Wang et al.,
2006

Barber et al., 1999;
Wang et al., 2006

Wang et al., 2006

Wang et al., 2007

Wang et al., 2006

Haubst et al., 2004;
Ton et al., 1991;
Glaser et al., 1992
Haubst et al., 2004;
Ton et al., 1991;
Glaser et al., 1992
Haubst et al., 2004;
Ton et al., 1991;
Glaser et al., 1992
Haubst et al., 2004;
Ton et al., 1991;
Glaser et al., 1992
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Table 1. Continued

Pax6 variant 7
Pax7 variant 1
Pax7 variant 2

Pax7 variant 3

Pax8a

Differs in the 5 UTR compared with variant 1. Variants 1, 3, 6 and
7 encode the same isoform (a).
Encodes the longest Pax7 isoform

Neurogenesis, proliferation, regionalisation
and boundary formation

Uses an alternate in-frame splice site compared with variant 1.
The resulting isoform has the same N and C termini but is two
amino acids shorter than variant 1.
Differs in the 3 UTR and coding sequence compared with variant
1. The resulting isoform has a shorter and distinct C terminus
compared with variant 1.
Encodes the longest Pax8 isoform

A more potent transactivator of Cntfr (White
and Ziman, 2008);

Activating domain encoded by exons 10 and
11
Pax8b
Uses an alternate splice site in the 3 coding region compared with Antagonistic role to the activating domain
isoform Pax8a that results in a frameshift and an early stop
codon. It encodes an isoform that has a shorter and distinct
C terminus compared to Pax8a.
Pax8d
Lacks two alternate exons compared with isoform Pax8a that
results in a frameshift and an early stop codon. The encoded
isoform is shorter and has a distinct C terminus compared with
Pax8a.
Pax8e
Lacks three alternate exons compared to isoform Pax8a that
results in a frameshift and an early stop codon. The encoded
isoform is shorter and has a distinct C terminus compared with
Pax8a.
Pax9
No data available on NCBI
Cntfr, ciliary neurotrophic factor receptor.

cartilage and bone originate from NC cells (Le Douarin et al.,
2008), and Pax3 and Pax7 play key roles in their specification,
migration and differentiation into the various tissue lineages and
regions. Initially, cells of the neural plate border respond to signals
from the neural plate that upregulate Pax3, Pax7, Zic1 (zinc finger
protein of the cerebellum 1), and Msx1 and Msx2, early markers
of the NC lineage in mice and genes required for NC induction
(Sato et al., 2005; Monsoro-Burq et al., 2005; Basch et al., 2006).
Notably, the role of Pax3 and Pax7 during specification of the NC
lineage is distinct in chick and Xenopus when compared with
mouse (Sato et al., 2005; Basch and Bronner-Fraser, 2006); in
mice, Pax3 and Pax7 function to upregulate the downstream NC
specifier genes Snail, Foxd3 (forkhead box D3) and Sox genes,
which are said to then ‘imbue’ the cell to become a competent NC
cell (Bronner, 2012).
Although the structures of their DNA-binding domains are similar
(Vorobyov et al., 1997), differences in Pax3 and Pax7 function and
regulation during NC development have been identified. Using
Pax7-cre/reporter mice, Pax7-expressing precursors were noted to
be distinct from Pax3-expressing NC precursors, and principally
contribute to the cranial NC derivatives of the frontal and parietal
bones of the skull, meninges, teeth, trigeminal ganglia, whisker
follicles, olfactory epithelium and cartilage of the nasal septum
(Engleka et al., 2005; Murdoch et al., 2012). Often thought to act in
a redundant manner in regions of overlapping expression, the two
proteins also exhibit differences in their regulatory mechanisms. The
Pax7 transactivation domain, for example, is sumoylated, whereas
the Pax3 transactivation domain is not. This post-translational
sumoylation of Pax7 has been shown to be essential for early NC
formation (Luan et al., 2013).

References
Haubst et al., 2004;
Ton et al., 1991
Glaser et al., 1992
Haubst et al., 2004;
Ton et al., 1991;
Glaser et al., 1992
Vorobyov et al., 1997;
Barr et al., 1999
Vorobyov et al., 1997;
Barr et al., 1999
Jostes et al., 1990

Poleev et al., 1995
Poleev et al., 1995

Poleev et al., 1995

Pax3 has a crucial role in the induction and specification of NC
cells. Using pluripotent cells of the Xenopus blastula in vitro, it was
shown that electroporation of a Pax3/Zic1 construct prior to
neurulation induced the early NC specifiers snail1, sox8 and myc in
cells that went on to undergo an epithelial-to-mesenchymal transition,
detach from the explant and migrate in vivo following
xenotransplantation into a host embryo. Pax3/Zic1-induced and
grafted NC cells followed normal NC migration paths and were seen
frequently to develop into pigmented melanocytes and chondrocyte
cells (Milet et al., 2013). Pax3 also regulates Hes1 (hairy and enhancer
of split 1; which is involved in neural stem cell maintenance),
Neurog2 (which is involved in NC neurogenesis) and Tgfb2
(transforming growth factor β2) (which in turn represses Pax3
promoter activity on Hes1 and Neurog2) (Theriault et al., 2005;
Mayanil et al., 2006; Nakazaki et al., 2008; Medic and Ziman, 2010).
Using mice bred for a double heterozygous Pax3 and Tgfb2
phenotype, Nakazaki et al. (Nakazaki et al., 2009) demonstrated that
the Tgfb2−/− Pax+/+ phenotype of open neural tube and bifid spine was
reversed in 85% of animals following the loss of one Pax3 allele
(Tgfb2−/− Pax+/−). Results were attributed to the opposing roles of
PAX3 and TGFβ2 in the regulation of Hes1, Neurog2 and Sox9, as
seen in earlier studies (Mayanil et al., 2001; Zavadil et al., 2001).
Following this, a model was described in which the regulatory
network between Pax3, Tgfb2, Hes1, Neurog2 and Sox9 functions to
maintain NC cells in an undifferentiated state prior to migration while
ensuring progenitor cell identity is specified through appropriate
timing of Hes1, Neurog2 and Sox9 expression (Nakazaki et al., 2009).
Nakazaki et al. also discussed a possible role for Pax3 and Tgfb2
in remodelling of the extracellular matrix to facilitate NC cell
migration (Nakazaki et al., 2009); however, the continuing
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Transcript name Description
Function
Pax6 variant 5
Differs in the 5 UTR and includes an alternate exon in the coding Overexpression leads to proliferation
region that maintains the reading frame compared with variant 1.
Variants 2, 4 and 5 encode the same isoform (b), which is
shorter than isoform a.
Pax6 variant 6
Differs in the 5 UTR compared with variant 1. Variants 1, 3, 6 and Neurogenesis, proliferation, regionalisation
7 encode the same isoform (a).
and boundary formation

PRIMER
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Table 2. PAX mutations and associated phenotypes
Name/species

Mutation

Pathology

References

‘Undulated’/mouse

G15S (paired-domain)
Pax1
2.0 kb and 4.5 kb
deletions exons 1 to 4,
respectively, in Pax1

Abnormalities in the sternum and parts of the
vertebral column in heterozygotes
Homozygous mice show lumbar scoliosis and a
kinked tail

Balling et al., 1988

Papillorenal
syndrome/human

Heterogeneous mutations Ocular and renal anomalies, vesicoureteral reflux,
to PAX2
high frequency hearing loss, central nervous
system anomalies and/or genital anomalies

Craniofacial-deafnesshand syndrome/human

Ketosis-prone diabetes
mellitus/human
Diabetes mellitus, type
2/human
Lymphoplasmacytoid
lymphoma/human
Small eye/mouse

Asn47-to-lys; asn47-to-his Flat facial profile, hypertelorism, hypoplastic nose
(paired domain) PAX3
with slitlike nares, sensorineural hearing loss.
small maxilla, absent or small nasal bones and
ulnar deviation of the hands
Translocation of the PAX3 Childhood sarcoma
gene on chromosome 2
or PAX7 gene on
chromosome 1 with the
FKHR/FOXO1A gene
on chromosome 13
Heterogeneous mutations Pigmentary abnormalities of the hair, skin and
in PAX3
eyes; congenital sensorineural hearing loss;
dystopia canthorum; lateral displacement of the
ocular inner canthi
Heterogeneous mutations Pigmentary abnormalities of the hair, skin and
in PAX3
eyes; congenital sensorineural hearing loss;
dystopia canthorum; lateral displacement of the
ocular inner canthi and upper limb abnormalities
A-to-T transversion of the Neural tube, neural crest, severe limb and trunk
AG splice acceptor of
muscle defects
intron 3 of Pax3
G9R (paired domain)
Heterozygous animals have pigmentation defects
Pax3
with occasional neural tube defects; homozygous
animals have spina bifida with or without
exencephaly, spinal ganglia abnormalities and
delays in posterior neuropore closure and neural
crest cell emigration
Ethnic-specific gene
Severe hyperglycemia and ketosis
variants in PAX4
Hetergenous mutations of Weight loss, fatigue, polydipsia, polyuria and
PAX4
hyperglycemia
Haploinsufficiency of
Leukaemia
PAX5
Mutation in Pax6
Aniridia and corneal abnormalities

Aniridia/human

Mutation in PAX6

Rhabdomyosarcoma 2,
alveolar/human

Waardenburg syndrome,
type 1/human

Waardenburg syndrome,
type 3/human

‘Splotch’/mouse
‘Splotch-delayed’/mouse

Noticeable iris hypoplasia

Coloboma of optic nerve/ Mutation in PAX6
human
Foveal hyperplasia/human Mutation in PAX6

Detachment of the macula

Gillespie syndrome/
human

Mutation in PAX6

Aniridia, cerebellar ataxia and mental retardation

Keratitis/human
Optic nerve hypoplasia/
human
Peters anomaly/human

Mutation in PAX6
Mutation in PAX6

Hypothyroidism,
congenital, due to
thyroid dysgenesis or
hypoplasia/human
Tooth agenesis, selective,
3/human

Heterogenous mutations
of PAX8

Childhood corneal clouding
Bilateral optic nerve hypoplasia, poor visual acuity
and wandering movements of the eyes
Central corneal leukoma, absence of the posterior
corneal stroma and lenticular attachments to the
central aspect of the posterior cornea
Congenital hypothyroidism, ectopic thyroid gland,
athyreotic cretinism

Heterogenous mutations
of PAX9

Oligodontia and hypodontia

‘Pax9-neo’/mouse

Hypomorphic Pax9 allele

Oligodontia
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Mutation in PAX6

Subnormal visual acuity and congenital nystagmus

Adham et al., 2005

Schimmenti et al., 1997; Eccles and
Schimmenti, 1999; Tellier et al., 1998;
Devriendt et al., 1998; Amiel et al., 2000;
Nishimoto et al., 2001; Higashide et al.,
2005; Bower et al., 2012
Hoth et al., 1993; Asher et al., 1996

Douglass et al., 1987; Wang-Wuu et al., 1988;
Hayashi et al., 1988; Barr et al., 1991; Barr
et al., 1993; Fredericks et al., 1995

Tassabehji et al., 1992; Baldwin et al., 1992;
Ishikiriyama, 1993; Baldwin et al., 1995

Hoth et al., 1993; Zlotogora, 1995; Tekin et al.,
2001; Wollnik et al., 2003

Epstein et al., 1991
Yang and Trasler, 1991

Sobngwi and Gautier, 2002; Mauvais-Jarvis
et al., 2004
Shimajiri et al., 2001
Nutt and Busslinger, 1999; Rolink et al., 1999;
Mullighan et al., 2007
Glaser et al., 1990; Hill et al., 1991; Matsuo
et al., 1993; Ramaesh et al., 2003;
Ramaesh et al., 2006
Shaw et al., 1960; Elsas et al., 1977; Glaser
et al., 1994; Sisodiya et al., 2001
Jonas and Freisler, 1997; Hornby et al., 2000;
Azuma et al., 2003
O’Donnell and Pappas, 1982; Hanson et al.,
1999; O’Donnell and Pappas, 1982; Curran
and Robb, 1976; Oliver et al., 1987; Azuma
et al., 1996; Hanson et al., 1999
Gillespie, 1965; Sarsfield, 1971; Crawfurd
et al., 1979; Lechtenberg and Ferretti, 1981;
Wittig et al., 1988; François et al., 1984;
Nelson et al., 1997; Verhulst et al., 1993;
Ticho et al., 2006; Graziano et al., 2007;
Kivlin et al., 1986; Pearce et al., 1995;
Hackenbruch et al., 1975; Azuma et al., 2003
Hanson et al., 1994; Yang et al., 2004

Macchia et al., 1998; Vilain et al., 2001;
Congdon et al., 2001; Meeus et al., 2004

Stockton et al., 2000; Das et al., 2002; FrazierBowers et al., 2002; Lammi et al., 2003;
Mostowska et al., 2006; Kapadia et al., 2006
Kist et al., 2005
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Caudal
metencephalon

Pax6:En1/Pax2

En1/Pax2

Pax6
Pax2 –/–
Intrinsic/extrinsic repression of
Pax2

Pax6 specified

B Pax2/5 mutants

Pax6 –/–
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Pax6
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Fig. 2. Regional specification of brain neuroblasts. (A) In the early brain,
Pax6 (green) is strongly induced in the rostral region as Pax2 (red) is induced
in the caudal region, giving rise to an overlap in Pax6 and Pax2 expression at
the di-mesencephalic boundary. In this region of overlapping expression,
Pax6 and Pax2 are proposed to repress each other by indirect and direct
molecular mechanisms until their expression domains are completely
segregated, thus forming the di-mesencephalic boundary. (B) In Pax2– Pax5–
mice, the mesencephalon primordium is lost due to expanded expression of
Pax6 (Schwarz et al., 1999). (C) Altered regionalisation, such as that
occurring in Pax6 Sey mutant mice (which harbour a mutation in the donor
splice site for exon 10 of Pax6), leads to a misexpression of genes that are
characteristic of the neighbouring brain region and a change in neuronal fate
(Mastick et al., 1997).

uncertainty about Pax3 requirement for NC migration (Li et al.,
1999; Conway et al., 2000; Kwang et al., 2002; Chan et al., 2004)
has been addressed recently by looking at the role of Pax3 in
migratory cardiac NC cells using the Pax3 mutant Splotch mouse
models, all six of which have different mutations in Pax3 (Table 2).
In all Splotch mice, cardiac NC cells fail to undergo proliferative
expansion prior to migration due to defects intrinsic to the NC cell.
The resulting reduced number of migratory cardiac NC cells in the
outflow region of the heart leads to hypoplasia of the posterior
pharyngeal arch arteries, vessel destabilisation, lack of septation, an
aortic arch at the cervical level and loss of ductus arteriosus
(Conway et al., 1997). Importantly, recent studies of a conditional

allele with targeted lineage-restriction deletion of Pax3 around E8.0
revealed that Pax3 plays an essential role in early NC progenitor
formation and specification, but is not required for progeny
migration or morphogenesis of the outflow tract of the heart (Olaopa
et al., 2011).
It is still not known whether NC cells are lineage restricted before
or after emigration from the neuraxis. In mice, premigratory and
migratory NC cells have been identified as multipotent using in vivo
single cell dye injection and tracking methods (Serbedzija et al.,
1994); avian NC cells, however, appear fate restricted just after
emergence from the neuraxis (Henion and Weston, 1997) where
timing of emigration correlates with localisation to particular
pathways and, ultimately, to fate restriction (Krispin et al., 2010).
The fate restriction of NC cells is particularly intriguing in relation
to Pax3 expression and Schwann cell or melanocyte development.
For example, the dorsolateral region between the dermomyotome
and the ectoderm is populated by cells that eventually target the
skin, and these ‘specified’ melanoblasts express Mitf
(microphthalmia-associated transcription factor), a downstream
target of PAX3 (Lang et al., 2005). Mitf is known to be necessary
for the survival and proliferation of melanoblasts at this stage of
development (Opdecamp et al., 1997; Hornyak et al., 2001) and
largely controls the melanocytic gene program. Studies have shown
that although Pax3 initiates Mitf expression, it functions at the same
time to prevent MITF from activating melanocyte genes until
external stimuli in the target skin relieve PAX3 repressive effects
(Lang et al., 2005). Thus, although lineage-specific transcription
factors such as MITF prime the fate of a cell from early stages of
NC emigration, migratory cells are inhibited from differentiation by
temporal and environmental effects (Basch et al., 2006; Bronner,
2012). This is the melanocytic example of the ‘on-off’ Pax switch,
or capacitator, so eloquently described by Lang et al. (Lang et al.,
2005).
In an earlier wave of NC migration, at E11 in mouse, NC progeny
also migrate in ventral pathways along developing axons prior to
acquisition of either a Schwann or melanocyte fate (Jessen and
Mirsky, 2005; Adameyko et al., 2009; Adameyko and Lallemend,
2010; Ernfors, 2010). These bi-potent NC derivatives are termed
precursor Schwann/melanocyte (PSM) cells and their fate is largely
controlled by association with axonally secreted neuregulin (for
adoption of glial fate) or insulin-like growth factor 1 (IGF1) and
platelet-derived growth factor (PDGF) (for melanocyte
specification) (Adameyko et al., 2009; Adameyko and Lallemend,
2010). As PSM cells migrate along established β-neuregulin 1secreting axon tracts, their maintenance is regulated by Sox2, Sox10
(Britsch et al., 2001; Le et al., 2005) and Pax3 (Blanchard et al.,
1996; Kioussi et al., 1995). Pax3 is a known survival factor for PSM
cells during this mitotic and chemotactic stage; when homozygous
Splotch mice perish at E13.5, PSM cells cannot be detected (Franz,
1990) and mice homozygous for the Splotch-delayed allele (Table 2)
(which survive until E18.5) contain few PSM cells, all of which
perish by E15.5 (Moase and Trasler, 1990).
The transition from PSM cell to immature Schwann cell (ISC) or
to melanoblast occurs between E12 and E16. During this time, PSM
cells penetrate between axons and fated ISCs begin to engage in
radial axonal sorting, a period of extensive mitotic and apoptotic
activity that results in the requisite ratio of glial cells to axons (Yu
et al., 2005). At the same time, some PSM cells are driven toward a
melanoblast fate due to increasing levels of IGF1 and PDGF, and to
inhibition of axonal contact (Adameyko and Lallemend, 2010)
(Fig. 3). It is notable that Pax3 expression is downregulated in this
pathway from E13.5 to E18.5 (Kioussi et al., 1995) as in vitro
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studies have shown that Pax3 induces proliferation and inhibits
apoptosis of Schwann cells (Doddrell et al., 2012) and also has a
principal role in the regulation of dorsolateral melanocyte
differentiation (Lang et al., 2005). Downregulation of Pax3
correlates with Oct6 and Krox20 (Egr2; early growth response 2)
upregulation (which occurs at E17-P3) in promyelinating Schwann
cells (Blanchard et al., 1996) and supports the supposition that Pax3
inhibits the myelination gene program (Kioussi et al., 1995;
Doddrell et al., 2012). It is certainly intriguing to consider possible
Pax3, Sox10, Mitf, Nrg1 (neuregulin 1), Igf1 and Pdgf gene
regulatory networks that function in the specification of ISCs versus
melanoblasts at this stage. Moreover, further study is required to
compare and contrast the role of Pax3 in the development of
Schwann cells and melanoblasts in the ventral NC pathway as
several authors have proposed a link between these progenitors and
cutaneous melanoma (Hoerter et al., 2012; Cramer and Fesyuk,
2012).
Morphogenesis of the vertebral column and skeletal musculature

Toward the end of the second week after human conception, tissue
masses known as somites occupy the entire length of the trunk on
both lateral aspects of the neural tube. These then become
progressively organised into the vertebral column and skeletal
muscle, which are characteristic of the segmented vertebrate. The
somites, which are derived from paraxial mesoderm, are initially
pseudostratified epithelial progenitor cells (Nitzen and Kalcheim,
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2013). Cells of the ventromedial part of the somite de-epithelialise,
migrate and condense as sclerotome near the notochord and
contribute to vertebral bodies, spinal pedicles, neural arch and
costal processes (Nitzen and Kalcheim, 2013). Sclerotomal
expression of Pax1 and Pax9 is dependent upon Shh secretion
from the notochord, and evidence supports the fact that Pax1 is
necessary for the specification of ventral sclerotome cells that
accumulate prior to chondrogenesis (Christ et al., 2000). In these
cells, Pax1 and Pax9 are required to maintain a high rate of
proliferation, thus enabling the precursor pool to reach a critical
size and proceed into sclerotome-specific developmental programs
(Peters et al., 1999).
Medially, somitic epithelial cells generate myocytes, which
dissociate to form a rostral/caudal scaffold of nascent muscle fibres
adjacent to the developing dorsal dermamyotome (DM). The DM
retains its epithelial characteristic, which consists of multipotent
progenitors that will generate myogenic, endothelial and dermal
cells (Ben-Yair and Kalcheim, 2008). The DM elongates
dorsomedially and ventrolaterally with a secondary generation of
DM-derived myocytes that delaminate and intercalate among
previously scaffolded muscle fibres to colonise the developing
epaxial and hypaxial myotome (Nitzan and Kalcheim, 2013). During
this somitic patterning phase, Pax3 is expressed in the presomitic
mesoderm and throughout the early somite (Goulding et al., 1991).
As the dermomyotome matures, Pax3 becomes restricted to the
epaxial and hypaxial lips (Galli et al., 2008), and, in epaxial cells, it

Development

Fig. 3. Development of Schwann cells and melanocytes from neural crest cells. Melanoblasts diverge from bi-potent precursors around the time that
radial axonal sorting occurs among immature Schwann cells (E12-E16 indicated by the blue window) and is linked to a lack of access to nerve-secreted growth
factors. The divergent specification of immature Schwann cell and melanoblast occurs during a period marked by an absence of Pax3 expression (E13.5-E18
indicated by the red window) (Kioussi et al., 1995). The developmental time scale is indicated along the bottom. Genes or proteins expressed in each cell type
are also indicated. DCT, dopachrome tautomerase; ERBB3, V-ERB-B2 avian erythroblastic leukemia viral oncogene homolog 3; GFAP, glial fibrillary associated
protein; IGF, insulin-like growth factor; MITF, microphthalmia-associated transcription factor; KROX20, early growth response 2 (EGR2 – Mouse Genome
Informatics); MBP, myelin basic protein; OCT6, POU domain, class 3, transcription factor 1; p75NGFR, nerve growth factor receptor; P0, myelin protein zero;
PAX, paired homeobox; PDGF, platelet-derived growth factor; S100, S100 calcium-binding protein; SOX, sex-determining region Y;

is thought to upregulate the myogenic regulatory factor Myf5
(myogenic factor 5) through synergy with ZIC1 and GLI2 on the
Myf5 epaxial somite enhancer (Himeda et al., 2013).
In the limbs, Pax3+ progenitors delaminate from the hypaxial
dermamyotome and migrate into the developing limbs to provide a
pool of progenitors for subsequent myogenesis. In these cells, Pax3
regulates the hepatocyte growth factor receptor Met, which is
necessary for hypaxial delamination and migration (Dietrich, 1999);
in the limbs, postnatal myogenesis is induced by Pax3 via alternate
Myf5 regulatory enhancers (Bajard et al., 2006). In Pax3 mutant
embryos, there are abnormalities in segmentation and loss of epaxial
and hypaxial dermomyotome with consequent myotome
malformation and loss of trunk and limb musculature (Goulding et al.,
1993; Tremblay et al., 1998; Schubert et al., 2001).
Pax7 is also expressed in early epithelial somites, principally
within the central ‘sheet’ of DM cells; at this stage, Pax7 expression
is inversely correlated to myogenic differentiation (Galli et al.,
2008). When the final epithelial somite dissociates, a perpendicular
planar shift of cell division occurs in the central sheet concurrent
with generation of dermal and myoblast progenitors; here, Pax7+
myoblast progenitors undergo asymmetric division and delamination
results in the production of a basal Pax7+ daughter cell that is
directed into the developing myotome (Ben-Yair et al., 2011). It is
unknown whether this final DM dissociation produces multipotent
cells that are specified upon translocation to the dermis or myotome,
or whether there is an asymmetric allocation of cell fate
determinants to daughter cells.
As development proceeds, myotomal Pax3+ Pax7+ cells retain a
progenitor state to become a resident population necessary for
skeletal muscle growth (Buckingham and Relaix, 2007). In these
myogenic stem cells, the expression of Pax3 and Pax7 is negatively
correlated to that of Myod1, a myocyte marker (Galli et al., 2008).
During embryonic myogenesis, the balance between myogenic stem
cell self-renewal and differentiation is promoted by Notch or FGF,
respectively, where the latter signals myogenesis via upregulation of
Fgfr4 (fibroblast growth factor receptor 4) by PAX3 (Lagha et al.,
2008). Postnatal Pax3+ Pax7+ offspring either enter the myogenic
program through upregulation of the myogenic regulatory factors
Myf5 and Myod1 or retain a Pax3+ Pax7+ Mrf– (myelin regulatory
factor; Myrf – Mouse Genome Informatics) phenotype and align
with nascent myotubes to become resident adult stem cells, known
as satellite cells (Relaix et al., 2005). Pax7 mutant mice do not have
embryonic skeletal muscle defects; however, Pax7 is required for
the postnatal survival of satellite cells and hence adult muscle
regeneration (Seale et al., 2000; von Maltzahn et al., 2013). In adult
myogenesis, Pax7 inactivation during satellite cell proliferation
results in loss of satellite cells and reduced heterochromatin
condensation in the rare satellite cells that survive (Günther et al.,
2013). Pax3 is also expressed in adult satellite cells (Buckingham et
al., 2003) and although its role in these cells remains unknown,
Soleimani et al. (Soleimani et al., 2012) have described alternate
affinities for paired box- and homeobox-binding motifs that are
thought to result in alternate Pax7 and Pax3 target gene regulation
in adult satellite cells.
Finally, in the trunk, a fourth somitic compartment, known as the
syndetome, originates from the dorsolateral edge of the sclerotome
as interactions between skeletal muscle and cartilage lead to
specification of tendon progenitors. In this region of sclerotomal
condensation, both Pax1 and Pax9 are downregulated once
chondrogenesis is initiated (Christ et al., 2000; Brand-Saberi and
Christ, 2000). This relieves repression of scleraxis (Scx), the de novo
expression of which leads to tendon specification in the cells that
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adjoin skeletal muscle and chondrogenic tissue (Brent et al., 2003)
(Fig. 4).
Pax genes in tissue regeneration and disease states

The important roles of Pax genes in development underscores their
function in adult tissue regeneration and the repercussions of their
aberrant loss, overexpression, re-expression or persistent expression
in association with pathology (Table 2) and, in particular, cancer (Li
and Eccles, 2012). The Pax functions outlined thus far lend credence
to the hypothesis that perturbed Pax-expressing cells ‘hijack’
associative signalling pathways and/or transcription networks,
leading to uncontrolled growth and survival. As we discuss below,
Pax genes continue to function in the adult organism with a principal
role in the regulation of lineage specification and maintenance of a
stem-like state in progenitor cells. It is important to realise, however,
that the mechanisms of Pax action in adult stem and progenitor cells
does not fully recapitulate developmental programs, as fate
conversion of adult stem cells is also tightly linked to the stem cell
niche environment and to other intrinsic mechanisms (Ninkovic et
al., 2013).
Aberrant Pax gene expression: implications for regeneration and
disease

Childhood alveolar rhabdomyosarcoma (ARMS), a malignant soft
tissue tumour that occurs in adolescents and young adults, is one
example in which aberrant Pax gene expression leads to cellular
oncogenic transformation. ARMS cells express a gene fusion resulting
from a t(2;13) or t(1;13) translocation of the PAX3 or PAX7 PD- and
HD-encoding regions, respectively, with the transactivation domain
of the homeotic gene forkhead box O1 (FOXO1, also known as
FKHR and FOXO1A). The resulting PAX3/FOXO1 fusion protein
exhibits a greater than 100-fold gain-of-function effect on PAX3
downstream target genes and a dominant-negative effect on wild-type
PAX3 expression (Bennicelli et al., 1996). Cellular pathways and
mechanisms affected by aberrant PAX3:FOXO1 expression include
MET signalling (which stimulates cell cycle following postnatal
muscle injury), FGF receptor 4- and IGF receptor-mediated growth,
and chromatin remodelling, which allows activation of MYOD1 target
genes (Keller and Guttridge, 2013).
As a large percentage of paediatric rhabdomyosarcomas arise
after the first year of life, muscle satellite cells have been proposed
as the cell of origin for ARMS. However, the consequences of late
embryonic activation of Pax3:Fkhr using a conditional Pax3:Fkhr
knock-in allele demonstrated that pre- and postnatal Pax3:Fkhr
expression in satellite cells does not lead directly to ARMS (Keller
et al., 2004). The rhabdomyoblast, a signature multinucleated cell
type seen in ARMS, has also been hypothesised as the transformed
progeny of an activated satellite cell or mesenchymal stem cell that
contributes to skeletal muscle regeneration and, through several
PAX3-associated mechanisms, has been inhibited from
differentiation (Relaix et al., 2005; Roeb et al., 2007; Charytonowicz
et al., 2009). The cell of origin for ARMS thus remains to be clearly
identified.
An emerging concept is that PAX proteins have a role in the
epigenetic determination of active or silenced regions of DNA
(Dressler, 2011). In satellite cells, lymphoid progenitors and HEK
293 cells, PAX7, PAX5 and PAX2, respectively, have been shown
to recruit histone methyltransferase complexes to the promoter
regions (Patel et al., 2007) of genes such as Myf5 and Myod1
(McKinnell et al., 2008), where the PAX transactivation domain
links to methyltransferase complexes by an interacting protein (Cho
et al., 2003; Fang et al., 2009; Diao et al., 2012). Epigenetic
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repressive imprints have also been shown to be initiated by PAX
proteins through the recruitment of groucho-related gene product 4
(GRG4) to specify a region of chromatin for silencing; in
melanoblasts, lymphoid progenitors and HEK 293 cells, PAXmediated gene repression is associated with the recruitment of
GRG4, with both proteins interacting cooperatively for resultant
transcriptional repression (Eberhard et al., 2000; Lang et al., 2005;
Patel et al., 2013). Thus, aberrant PAX expression may fuel
oncogenesis through either forced epigenetic activation or repression
of downstream target genes, or through a loss of such PAX
controlled epigenetic modifications.
Cell specification and fate restriction have also been linked to the
compartmentalisation of the genome into active and inactive domains,
such that key developmental genes such as Pax are stably silenced in
differentiated cells. This epigenetic tenet must be reconsidered,
however, in the light of the PAX re-expression and re-repression that
occurs with some forms of homeostatic injury repair. For example, a
fundamental characteristic of peripheral nerve regeneration is the
ability of adult myelinating Schwann cells to revert from a postmitotic differentiated state into the cell cycle and back. In injured
nerves, as Schwann cells become demyelinated, Pax3 is upregulated
along with other immature Schwann cell genes (Kioussi et al., 1995).
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Once regenerated axons reach their target tissue, Pax3 levels peak as
the progeny of Schwann cells begin to reproduce myelin and, when
the myelinogenic program is well under way, Pax3 is downregulated
(Kioussi et al., 1995). Pax3 in regenerative Schwann cells, as in
embryogenesis, is thus thought to oppose myelination and withdrawal
from the cell cycle (Doddrell et al., 2012).
A similar phenotypic regression is seen in adult tubular cells when
Pax2 is re-activated during kidney repair. During normal nephron
development, Pax2 drives a pivotal mesenchymal-to-epithelial
transition event in which ureteric bud cells induce stems cells of the
metanephric mesenchyme to transition into epithelial cells
(Dziarmaga et al., 2003). However, in renal fibrosis, which is a
common manifestation of chronic kidney disease (Liu, 2004), adult
tubular cells lose their epithelial characteristics and readopt a
mesenchymal (stem cell) fate in order to be involved with injury
repair. Studies have shown that Pax2 and Wilms’ tumor 1 gene
(Wt1) are both required for mesenchymal-to-epithelial transition and
are re-expressed in animal and cell models of tubular epithelial-tomesenchymal transition during acute and chronic injury (Huang et
al., 2012). This so-called ‘atavistic’ phenotypic transition, which
triggers the genetic and cellular processes involved with the loss of
epithelial phenotype and reacquisition of an induced mesenchymal
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Fig. 4. Pax gene hierarchies involved in the development of the progenitor populations of skeletal muscle, cartilage and tendon. Cells in the
ventromedial part of the somite de-epithelialise and form the sclerotome (light green), in which Pax1 and Pax9 are expressed in a Shh-dependent manner. As
the dermomyotome elongates dorsomedially and ventrolaterally, PAX3 becomes restricted to the epaxial (red) and hypaxial (dark blue) lips, where a secondary
generation of myocytes delaminate and migrate to form the epaxial (orange) and hypaxial (light blue) myotome. In the limb region, PAX3+ progenitors
delaminate from the hypaxial dermamyotome (light blue) and migrate into the developing limbs to provide a pool of progenitors. In these cells, PAX3 regulates
the hepatocyte growth factor receptor Met, which is necessary for hypaxial delamination and migration. Pax7 is expressed principally within the central sheet of
the dermomyotome (purple); when the final somite dissociates, Pax7+ progenitors delaminate into the developing myotome. These myotomal Pax3+ Pax7+
cells (pink) retain a progenitor state in order to become a resident population necessary for skeletal muscle growth as development proceeds. The syndetome
(dark green) originates from the dorsolateral edge of the sclerotome, as Pax1 and Pax9 are downregulated and scleraxis (Scx) upregulation leads to
syndegenesis. Pax, paired homeobox; MYOD1, myogenic differentiation antigen 1; MYF5, myogenic factor 5; NKX, NK homeobox; SCX, scleraxis.

PRIMER

A role for Pax genes in cancer stem cells?

As Pax genes are responsible for the maintenance of a stem-like
phenotype, it is possible that they may be associated with
maintenance of the cancer stem cell phenotype, a key characteristic
of which is the capacity for the oncogenic cell to self-renew. Cancer
development is clearly associated with changes in the molecular
mechanisms that regulate stem cell differentiation (Perrotti et al.,
2010; Nguyen et al., 2012) that are thought inherited by amplified
progeny. In 2008, Rudnicki et al. (Rudnicki et al., 2008), using a
Myf5-Cre knock in allele, revealed that a novel subset of Pax7expressing satellite cells does not express Myf5 and that these cells
give rise to Pax7+ Myf5+ cells through basal-apical asymmetric cell
divisions. Isolation and transplantation of these cells into muscle
revealed that they underwent differentiation while Pax7+ Myf5– cells
contributed to the satellite stem cell reservoir.
A subsequent study using transgenic Tg:Pax7-nGFP mice (in
which GFP expression reflected endogenous Pax7 expression
quantitatively) showed that, during muscle regeneration, Pax7nGFPHi cells retain template DNA strands and expressed stem cell
markers while Pax7-nGFPLo cells performed random DNA
segregation and were myogenically committed (Rocheteau et al.,
2012). Taken together, these studies support a role for Pax7 in the
acquisition of a stem cell fate, which is characterised by high levels
of PAX7 and the lack of myogenic fate marker expression such as
Myf5. The means by which this inheritance is designated is
associated with the genomic and/or epigenomic regulation of
stemness in stem cells (Kawabe et al., 2012) and looks to be an
intriguing area of future research in the cancer stem cell field.
Conclusions

Nine Pax genes have been characterised in mammals and they are
considered principal regulators of gene expression, supported by the
evolutionary conservation of the paired DNA-binding domain across
phylogenies. Pax genes have important roles in the formation of the
CNS, where crossregulatory feedback loops are thought to maintain

and stabilise developing regions of the brain and spinal cord such
that aberrant Pax gene expression perturbs neuronal fate. It is also
evident that Pax genes function in gene regulatory networks in
which graded gene expression outputs are the product of the robust
regulatory logic of the network. Furthermore, Pax genes often
function to control the balance between the proliferation and
differentiation of progenitors, and a characteristic Pax ‘on/off
switch’ has been described that temporally maintains a precursor in
a ‘pre-differentiation’ state while poised for capacitated
differentiation. The molecular control of the choice between
proliferation and differentiation is thought to be a result of the use
of distinct Pax DNA-binding subdomains. Developmental studies
have also shown that Pax genes play a prominent role in the fate
restriction, migration and differentiation of somitic and neural crest
cells, where restricted downstream target gene expression primes the
fate of the cell from early stages of cell identity. During emigration,
however, cells are concomitantly inhibited from differentiation by
Pax-mediated and environmental inhibitory effects.
Although we have focused here on the developing nervous
system, the neural crest and the musculature, Pax genes regulate
multiple transcriptional networks that function simultaneously to
confer cellular capacity to proliferate, assume a specific cell fate and
execute the differentiation program in the developing eye
(Marquardt et al., 2001; Farhy et al., 2013), the pancreas (Brun and
Gauthier, 2008; Gosmain et al., 2011; Hu He et al., 2011; Kooptiwut
et al., 2012; Pfeifer et al., 2013) and the kidney (Dressler, 2011). The
prominent roles for Pax genes are linked to the perturbed expression
of Pax genes seen in disease states. Importantly, miR-mediated
regulation of Pax proteins (Pasut and Rudnicki, 2012; Kredo-Russo
et al., 2012; Shalom-Feuerstein et al., 2012; Shaham et al., 2013)
and the role of Pax proteins in the epigenetic determination of active
or silenced regions of DNA is now coming to light that adds further
complexity to the causes and repercussions of aberrant Pax gene
expression that fuels oncogenesis and other disease.
Funding
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